linaclotide capsule  (AstraZeneca ltd)

Journal: Advances in Therapy

Article Title: Healthcare Utilization and Costs of Care in Patients With Irritable Bowel Syndrome With Constipation or Chronic Idiopathic Constipation After Initiating Oral Therapies: Real-World Analysis in the US Medicare Population

doi: 10.1007/s12325-025-03163-1

Figure Lengend Snippet: Sample attrition

Article Snippet: Regarding pharmacologic treatments, current clinical practice guidelines from the American Gastroenterological Association and the American College of Gastroenterology provide strong recommendations for treatment of CIC with linaclotide, plecanatide, or prucalopride following failure or intolerance to over-the-counter laxatives.

Techniques: Medications

Journal: Advances in Therapy

Article Title: Healthcare Utilization and Costs of Care in Patients With Irritable Bowel Syndrome With Constipation or Chronic Idiopathic Constipation After Initiating Oral Therapies: Real-World Analysis in the US Medicare Population

doi: 10.1007/s12325-025-03163-1

Figure Lengend Snippet: Baseline demographics, clinical, characteristics, HCRU, and costs, overall and by treatment groups

Article Snippet: Regarding pharmacologic treatments, current clinical practice guidelines from the American Gastroenterological Association and the American College of Gastroenterology provide strong recommendations for treatment of CIC with linaclotide, plecanatide, or prucalopride following failure or intolerance to over-the-counter laxatives.

Techniques: Medications

Journal: Advances in Therapy

Article Title: Healthcare Utilization and Costs of Care in Patients With Irritable Bowel Syndrome With Constipation or Chronic Idiopathic Constipation After Initiating Oral Therapies: Real-World Analysis in the US Medicare Population

doi: 10.1007/s12325-025-03163-1

Figure Lengend Snippet: Adjusted count ratios a and count differences for HCRU comparing treatment groups over 12 months follow-up

Article Snippet: Regarding pharmacologic treatments, current clinical practice guidelines from the American Gastroenterological Association and the American College of Gastroenterology provide strong recommendations for treatment of CIC with linaclotide, plecanatide, or prucalopride following failure or intolerance to over-the-counter laxatives.

Techniques: Medications

Journal: Advances in Therapy

Article Title: Healthcare Utilization and Costs of Care in Patients With Irritable Bowel Syndrome With Constipation or Chronic Idiopathic Constipation After Initiating Oral Therapies: Real-World Analysis in the US Medicare Population

doi: 10.1007/s12325-025-03163-1

Figure Lengend Snippet: Adjusted cost ratios a and cost differences comparing treatment groups over 12 months follow-up

Article Snippet: Regarding pharmacologic treatments, current clinical practice guidelines from the American Gastroenterological Association and the American College of Gastroenterology provide strong recommendations for treatment of CIC with linaclotide, plecanatide, or prucalopride following failure or intolerance to over-the-counter laxatives.

Techniques:

Journal: Advances in Therapy

Article Title: Healthcare Utilization and Costs of Care in Patients With Irritable Bowel Syndrome With Constipation or Chronic Idiopathic Constipation After Initiating Oral Therapies: Real-World Analysis in the US Medicare Population

doi: 10.1007/s12325-025-03163-1

Figure Lengend Snippet:

Article Snippet: Regarding pharmacologic treatments, current clinical practice guidelines from the American Gastroenterological Association and the American College of Gastroenterology provide strong recommendations for treatment of CIC with linaclotide, plecanatide, or prucalopride following failure or intolerance to over-the-counter laxatives.

Techniques: